Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibogaine to Determine Maximum Tolerated Dose (MTD) or Treat-to-Target Dose (TTD) for the Evaluation of Efficacy and Safety

NCT05029401 is registered in ClinicalTrials.gov with atai Therapeutics, Inc. as lead sponsor.

NCT NCT05029401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibogaine to Determine Maximum Tolerated Dose (MTD) or Treat-to-Target Dose (TTD) for the Evaluation of Efficacy and Safety
Lead sponsor
atai Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2021
Completion date
January 16, 2024
Enrollment
116 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

opiate withdrawal syndrome